By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


SEARCH JOBS








Company News
Agios Pharmaceuticals (AGIO) Announces Initiation Of A Phase 1/2 Clinical Trial Of AG-221 In Patients With Advanced Solid Tumors With An IDH2 Mutation 10/21/2014 7:42:29 AM
Agios Pharmaceuticals (AGIO) Smart Buy Ahead Of Cancer Data: Citi 10/16/2014 2:20:13 PM
Agios Pharmaceuticals (AGIO) Announces Initiation Of Four Expansion Cohorts In Phase 1 Study Of AG-221 10/15/2014 7:43:47 AM
Agios Pharmaceuticals (AGIO) To Webcast R&D Day On October 15, 2014 10/6/2014 7:39:24 AM
Agios Pharmaceuticals (AGIO) To Present Clinical Data From AG-120 Ongoing Phase 1 Study In Hematologic Malignancies At EORTC-NCI-American Association for Cancer Research 2014 9/26/2014 8:22:08 AM
Agios Pharmaceuticals (AGIO) To Present At The 2014 Leerink Partners Rare Disease Roundtable 9/24/2014 7:20:18 AM
Agios Pharmaceuticals (AGIO) Announces The U.S. FDA Grants Fast Track Designation To AG-221 For Treatment Of Patients With Acute Myelogenous Leukemia That Harbor An IDH2 Mutation 8/13/2014 7:27:33 AM
Agios Pharmaceuticals (AGIO) Reports Second Quarter 2014 Financial Results 8/7/2014 8:57:53 AM
Agios Pharmaceuticals (AGIO) To Webcast Conference Call Of Second Quarter 2014 Financial Results On August 7, 2014 7/28/2014 7:40:02 AM
New Agios Pharmaceuticals (AGIO) Clinical Data From Ongoing Phase 1 Trial Of AG-221 Continue To Show Complete And Durable Remissions In Patients With Difficult To Treat Hematologic Malignancies 6/16/2014 10:19:30 AM
12345678
//-->